Drug Enforcement Administration, Department of Justice.
This final order establishes the initial 2020 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.
Effective Date: This order is effective December 2, 2019.
Start Further Info
FOR FURTHER INFORMATION CONTACT:
Scott A. Brinks, Diversion Control Division, Drug Enforcement Administration, 8701 Morrissette Drive, Springfield, VA 22152, Telephone: (571) 362-3261.
End Further Info
Start Supplemental Information
Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. 826) requires the Attorney General to establish aggregate production quotas for each basic class of controlled substance listed in schedule I and II and for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. The Attorney General has delegated this function to the Administrator of the Drug Enforcement Administration (DEA) pursuant to 28 CFR 0.100.
The 2020 aggregate production quotas and assessment of annual needs represent those quantities of schedule I and II controlled substances and the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine that may be manufactured in the United States in 2020 to provide for the estimated medical, scientific, research, and industrial needs of the United States, for lawful export requirements, and for the establishment and maintenance of reserve stocks. These quotas include imports of ephedrine, pseudoephedrine, and phenylpropanolamine, but do not include imports of controlled substances for use in industrial processes.Start Printed Page 66015
On September 12, 2019, a notice titled “Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2020” was published in the Federal Register. 84 FR 48170. This notice proposed the 2020 aggregate production quotas for each basic class of controlled substance listed in schedules I and II, and the 2020 assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. All interested persons were invited to comment on or object to the proposed aggregate production quotas and the proposed assessment of annual needs on or before October 15, 2019.
Within the public comment period, DEA received 731 comments from DEA registrants, hospital associations, professional associations, doctors, nurses, health system organizations, State Attorneys General, and others. The comments included concerns about the quota process, concerns that further quota reductions will lead to drug shortages, requests for less interference in the doctor-patient relationship, availability of prescription drugs for chronic pain patients, requests for hearings, requests for increase in specific production quotas, and other comments outside the scope of this notice. DEA received a joint comment from two Senators urging DEA to apply DEA's new authorities to prevent and limit opioid diversion due to excessively high production levels. Although this comment was received after the close of the comment period, DEA shares the Senators' concerns and is working to improve its ability to use available databases to better quantify diversion as part of the quota process.
There were non-DEA registered commenters that expressed concerns about the decrease in aggregate production quotas. These commenters alleged that decreases to the aggregate production quotas have resulted in a shortage of injectable opioid medications and interfere with the treatment of patients. Some of these commenters also suggested that DEA separate quotas for solid oral controlled substances and injectable controlled substances, and that DEA allow consideration by individual pharmaceutical dosage forms.
DEA also received letters from many doctors, nurses, hospital administrators, and others in the medical field regarding the proposed quota reduction for fentanyl and other schedule II narcotics. These letters characterized the reductions as “extremely problematic for American healthcare providers,” stating that the reduction for fentanyl and other schedule II narcotics will lead to drug shortages, raise drug prices, lead to hardships on hospitals and surgical facilities, and negatively impact patients. These letters discussed fentanyl's appearance on the Food and Drug Administration's (FDA) drug shortage list and that fentanyl is the least diverted among the covered controlled substances.
DEA is committed to ensuring an adequate and uninterrupted supply of controlled substances in order to meet legitimate medical, scientific, and export needs of the United States. Although DEA sets the aggregate production quota, it is possible that manufacturers' business practices may lead to a shortage of controlled substances at the consumer level, despite the adequacy of the aggregate production quota set by DEA. The aggregate production quotas are set by DEA in a manner to include both injectable opioids and solid oral opioids in order to ensure that the estimated medical needs of the United States are met.
Pursuant to 21 U.S.C. 826(a)(1), “production quotas shall be established in terms of quantities of each basic class of controlled substance and not in terms of individual pharmaceutical dosage forms prepared from or containing such a controlled substance.” However, the Substance Use-Disorder Prevention that Promotes Opioid Recovery Treatment for Patients and Communities Act of 2018 (SUPPORT Act), (Pub. L. 115-271), provides an exception to that general rule by now giving DEA the authority to establish quotas in terms of pharmaceutical dosage forms if the agency determines that doing so will assist in avoiding the overproduction, shortages, or diversion of a controlled substance. While DEA is now allowed to issue quotas in terms of pharmaceutical dosage form, it is not required to do so. DEA will not be utilizing this authority at the aggregate production quota level, but will be doing so at the individual dosage-form manufacturing level where it will have a greater impact on averting potential shortages. Because quotas set at the individual dosage-form manufacturing level are more directly connected to distributions of current and new FDA-approved drug products, they allow DEA to manage manufacturing quotas to alleviate any potential shortage in a more timely manner than with quotas set at the aggregate production quota level. This is also true because the aggregate production quota is initially established prior to the start of the quota calendar year.
Additionally, DEA and FDA can coordinate efforts to prevent or alleviate drug shortages pursuant to 21 U.S.C. 826(h). Such efforts may include adjusting domestic competitors' quota, completion of FDA approval to increase the number of competitors, and determining a foreign manufacturer that can meet FDA approval. For example, the domestic shortage of injectable hydromorphone that occurred in 2018 was alleviated through the collaboration of FDA and DEA to determine who were the other dosage-form manufacturers with injectable hydromorphone products in the market, whether other dosage-form manufacturers had the capability to increase their production levels to meet legitimate patient need in a timely manner, and when it was determined that the domestic manufacturers could not increase production significantly to meet legitimate patient need, DEA and FDA coordinated their regulatory authority to allow for the limited importation of injectable hydromorphone into the United States.
Relevant Information Obtained From the States
Pursuant to 21 CFR 1303.11, DEA must consider relevant information from the States when setting the aggregate production quota. Seven State Attorneys General submitted a joint comment expressing concerns about the estimation of diversion for all controlled substances, not accounting for over-prescribing, and the consideration of additional information to set quotas. Their concerns are addressed in more detail below.
I. Diversion Analysis for All Controlled Substances
The seven State Attorneys General commented that DEA should not take different approaches when accounting for diversion for the five covered controlled substances and the remaining controlled substances. In the letter, they discussed the mandates from the SUPPORT Act, as well as the requirements implemented through 21 CFR 1303.11 by the Controlled Substances Quota rule. 83 FR 32784. They expressed that they have similar language and purposes, even though the SUPPORT Act goes a bit further in its mandate by requiring the estimation of diversion for the five covered controlled substances. They pointed out that DEA Start Printed Page 66016estimated diversion and made straightforward quota reductions by the corresponding quantities, whereas DEA only noted that the databases contained usable information in regards to the remaining controlled substances. DEA did not indicate that diversion estimates were conducted for any other controlled substance, nor did DEA indicate that any corresponding decreases were made for other controlled substances. They commented that if DEA believes they have a sound method for estimating diversion, then it is unreasonable not to apply that method for estimating diversion to all controlled substances.
The States also commented that there is a lack of transparency in the setting of quotas. The States believe that DEA needs to explain the logic behind using different approaches in setting quotas. They commented that DEA must include the findings of fact when setting the quota and that transparency is essential in allowing parties to evaluate DEA's 2020 Proposed Aggregate Production Quota notice.
DEA considered various data sources in order to determine the extent of diversion of all controlled substances as is required by the recent amendments to the CSA and changes to DEA's own regulations. In accordance with factor six in 21 CFR 1303.11(b), DEA formally solicited the Department of Health and Human Services (HHS), U.S. Centers for Disease Control and Prevention (CDC), the Centers for Medicare and Medicaid Services (CMS), and the states in August 2018, requesting information including rates of overdose deaths and abuse and overall public health impact related to controlled substances. This information was also considered pursuant to the SUPPORT Act. DEA determined that due to the grouping of drug classes in all of the sources provided, the data could not be used to estimate diversion for the purpose of setting the aggregate production quotas. However, DEA estimated diversion of the covered controlled substances defined in the SUPPORT Act utilizing DEA's internal data sources. DEA will continue to further define sources that will be useful in analyzing diversion of the remaining controlled substances.
II. Methods and Data That Capture Over-Prescribing as Part of its Diversion Analysis
The States acknowledged that DEA's current approach for accounting for diversion is a significant improvement but commented that DEA does not adequately account for over-prescribing. They commented that over-prescribing results when there is overproduction, which allows legitimate prescriptions to be diverted. Assuming a controlled substance is validly dispensed for a legitimate medical purpose, both the physician and patient will use their judgement to determine how much medication will be prescribed and how much they will consume. The physician's decisions may be influenced by recommendations from CDC, FDA, and professional medical organizations that have conducted and/or reviewed clinical studies used to determine prescription guidelines. Patients are ultimately going to decide for themselves how much of the legitimately prescribed medication they will consume. DEA does not control the quantity of a substance prescribed to a patient, and DEA cannot control how much of the prescription a patient decides to consume. DEA also receives assistance in curbing overprescribing from programs in place, such as the President's Safer Prescribing Plan, which seeks to reduce nationwide opioid prescription fills by one-third. DEA has observed a decline in the number of prescriptions written for schedule II opioids since 2014 and will continue to set aggregate production quotas to meet the medical needs of the United States while combating the opioid crisis. These decreases take into account the combined efforts of DEA, FDA, and CDC enforcing regulations and issuing guidance documents, as well as many states enacting prescription monitoring database programs to stem the opiate/opioid epidemic.
There are ample reasons not to pursue the methods suggested by the State Attorneys General, including that the studies on which they relied are limited in scope of procedures and number of hospitals, such that the methodology is insufficient to expand to a national level.
As pointed out by the States, “there is no perfect system of measuring other sources of diversion like over-prescription.” The States pointed to data from drug takeback programs, but currently that data is not usable for consideration in determining the aggregate production quota. There is no method in place to determine how much of the prescription medications are schedule I or II substances and which controlled substances are being returned. DEA and HHS are working together to consider options for quantifying Take-Back Program data.
III. Consideration of Additional Information To Determine Production Quotas
The State Attorneys General commented that DEA should expand its sources of data used to set aggregate production quotas. They suggested three steps that DEA should take to gather information to set quotas which are listed below.
1: Improve Usability of the Automated Reports and Consolidated Ordering System (ARCOS) and the Suspicious Order Reporting System (SORS)
The State Attorneys General commented that DEA should improve usability of the ARCOS and SORS databases to gather better information on prescribing practices. They also note that DEA did not indicate whether SORS was used and minimally referred to ARCOS not being used because it contained identical information to the Theft Loss Report Database. The States commented that DEA needs to reform its process to upload SORS reports into the SORS database. Further, they commented that overdose data received from States and the CDC should be cross-referenced with ARCOS to provide context that should inform the quota-setting process.
SORS was not centralized until its recent launch on October 23, 2019. DEA will need time to sort through the system to determine its utility for aggregate production quota purposes. The submission of a suspicious order alone is not an automatic determination that the order is illicit in nature. Further investigations need to be completed to determine if a transgression has occurred.
The differences in reporting frequencies to ARCOS are specified in 21 CFR 1304.33(b). Acquisition and distribution transaction reports must be completed every quarter no later than the 15th day of the month succeeding the quarter for which it is being submitted. In the same section of the CFR, it does mention that a registrant may be given permission to file a report more frequently, but no more than on a monthly basis. The State Attorneys General request to change this regulation is outside of the scope of this final order.
2: Improve Data Collection in Prescription Drug Takeback Programs To Capture the Quantities of Drugs Overprescribed in Particular Areas
The State Attorneys General expressed that DEA should expand the National Take Back Program to assist with gathering more precise data on over-prescribing. They noted that the takeback programs do not track the types and quantities of what the public turns in, limiting their value. Currently, DEA and HHS are working together to consider methods that improve data Start Printed Page 66017collection and subsequently the usability of data obtained from the Take-Back Program.
3: Consider Medical Best Practices as Part of the Holistic Diversion Analysis
The letter submitted by the State Attorneys General also suggested that DEA study the best practices developed by the medical community and state regulators to determine what opioid quantities are “medically necessary.” They expressed that relying exclusively on evidence of illegal activity assumes that any legally-sold controlled substance is a part of the medical and scientific needs of the United States.
DEA is responsible for enforcing the provisions of the CSA and DEA regulations that require prescriptions for controlled substances to be issued by a practitioner for a legitimate medical purpose in the usual course of his/her professional practice. However, beyond that context, DEA does not regulate the practice of medicine generally and thus does not have a role in establishing the type of “best practices” to which the commenter refers.
Pain Management and Medical Associations Letters
DEA also received 106 comments that expressed concern that DEA's proposed reduction of opioids would adversely impact the availability of pain relieving prescription drugs for people with chronic pain. These comments were general in nature, and raised issues of specific medical illnesses and medical treatment, and therefore are outside of the scope of this Final Order. As a result, these comments did not provide new discrete data for consideration, and they do not impact the original analysis involved in establishing the 2020 aggregate production quotas.
DEA sets aggregate production quotas in a manner to ensure that all prescriptions that are authorized for legitimate medical purposes can be filled. Prescribers who are authorized to dispense controlled substances are responsible for adhering to the laws and regulations set forth under the CSA, which require doctors to only write prescriptions for legitimate medical needs. Any practitioner issuing an invalid prescription for controlled substances, and any pharmacy knowingly filling such a prescription, would be in violation of the CSA.
Two commenters urged DEA to hold a public hearing to receive feedback from stakeholders. They asked that DEA bring together all stakeholders, allowing stakeholders to publicly discuss their concerns.
Under the DEA regulations, the decision of whether to grant this type of a hearing on the issues raised by the commenters lies solely within the discretion of the Administrator. (21 CFR 1303.11(c) and 21 CFR 1303.13(c)). I find that neither of the foregoing two requests presented any evidence that would lead me to conclude that a hearing is necessary or warranted. Therefore, I decline to order a hearing on the issues presented by the commenters.
Specific Quota for DEA-Registered Manufacturers
The DEA received comments from five DEA-registered manufacturers regarding twenty-four different schedule I and II controlled substances. Commenters stated the proposed aggregate production quotas for amphetamine (for sale), fentanyl, hydromorphone, methylphenidate, morphine, noroxymorphone (for conversion), and oxycodone (for sale) were potentially insufficient to provide for the estimated medical, scientific, research, and industrial needs of the United States, export requirements, and the establishment and maintenance of reserve stocks. Commenters requested the proposed aggregate production quotas for FUB-144, 5F-AB-PINACA, 5F-EDMB-PINACA, 5F-MDMB-PICA, MMB-CHMICA, FUB-AKB48 (FUB-APINACA), 5F-CUMYL-PINACA, 5F-CUMYL-P7AICA, 4-CN-CUMYL-BUTINACA, NM2201, 4-Methyl-alpha-ethylaminopentiophenone (4-MEAP), N-Ethylhexedrone, 4-Chloro-alpha-pyrrolidinovalerophenone (4-Chloro-alpha-PVP), 4′-Methyl-alpha-pyrrolidinohexiophenone (MPHP), N-Ethylpentylone, alpha-Pyrrolidinohexanophenone (alpha-PHP), and alpha-Pyrrolidinoheptaphenone (PV8), be sufficient for additional quota requests.
DEA has considered the comments for specific controlled substances and made adjustments as needed which are described below in the section titled Determination of 2020 Aggregate Production Quotas and Assessment of Annual Needs. DEA received one comment to the proposed established 2020 assessment of annual needs for ephedrine, pseudoephedrine, and phenylpropanolamine regarding the difficulty in procuring finished dosage-forms of ephedrine. DEA has considered this comment in the section regarding drug shortages of controlled substances. This letter characterized the reductions of controlled substances and ephedrine as “extremely problematic for American healthcare providers,” stating that these reductions will lead to drug shortages, raise drug prices, lead to hardships on hospitals and surgical facilities, and negatively impact patients.
DEA is required under the CSA to establish quotas for ephedrine, pseudoephedrine, and phenylpropanolamine to provide for the estimated medical, scientific, research, and industrial needs of the United States, for lawful export requirements, and for the establishment and maintenance of reserve stocks. Although DEA sets the assessment of annual needs, it is possible that manufacturers' business practices may lead to a shortage of ephedrine drug products at the consumer level, despite the adequacy of the assessment of annual needs set by DEA. For instance, DEA does not have the authority to dictate when during the calendar year the manufacturer actually utilizes the quota granted to them. Also, DEA cannot dictate how much of the granted quota the manufacturer allocates for use in a single production run. The assessment of annual needs is set by DEA in a manner to include all dosage forms of ephedrine in order to ensure that the estimated medical needs of the United States are met.
Additionally, DEA and FDA can coordinate efforts to prevent or alleviate drug shortages. Such efforts may include adjusting competitors' domestic or import quotas and completion of FDA approval to increase the number of competitors.
Out of Scope
DEA received comments which addressed issues that are outside the scope of this final order. The comments were general in nature and raised issues of specific medical illnesses, medical treatments, and medication costs and, therefore, are outside of the scope of this Final Order. DEA also received comments asserting that illicit drug use, and not prescription drug use, is the main factor in the opioid crisis. Although DEA is genuinely concerned with illicit drug use and its involvement in the opioid crisis, the manufacturing of illicit substances is not considered when determining the aggregate production quotas because such illicit manufacturing cannot be tempered by adjusting the aggregate production quotas, therefore it is outside the scope of this final order.
All of these out of scope issues do not impact the original analysis involved in establishing the 2020 aggregate production quotas.Start Printed Page 66018
Determination of 2020 Aggregate Production Quotas and Assessment of Annual Needs
In determining the 2020 aggregate production quotas and assessment of annual needs, DEA has taken into consideration the above comments along with the factors set forth in 21 CFR 1303.11 and 21 CFR 1315.11, in accordance with 21 U.S.C. 826(a), and other relevant factors, including the 2019 manufacturing quotas, current 2019 sales and inventories, anticipated 2020 export requirements, industrial use, additional applications for 2020 quotas, as well as information on research and product development requirements. Based on all of the above, the Administrator is adjusting the 2020 aggregate production quotas for 4-Methyl-alpha-ethylaminopentiophenone (4-MEAP), N-Ethylhexedrone, 4-Chloro-alpha-pyrrolidinovalerophenone (4-Chloro-alpha-PVP), 4'-Methyl-alpha-pyrrolidinohexiophenone (MPHP), alpha-Pyrrolidinohexanophenone (alpha-PHP), alpha-Pyrrolidinoheptaphenone (PV8), amphetamine (for sale), oxycodone (for sale), and oxymorphone (for sale).
Regarding FUB-144, 5F-AB-PINACA, 5F-EDMB-PINACA, 5F-MDMB-PICA, MMB-CHMICA, FUB-AKB48 (FUB-APINACA), 5F-CUMYL-PINACA, 5F-CUMYL-P7AICA, 4-CN-CUMYL-BUTINACA, NM2201, N-Ethylpentylone, fentanyl, hydromorphone, methylphenidate, morphine, noroxymorphone (for conversion), and oxycodone (for sale), DEA has determined the proposed aggregate production quotas and assessment of annual needs are sufficient to provide for the 2020 estimated medical, scientific, research, industrial needs of the United States, export requirements, and the establishment and maintenance of reserve stocks. This final order establishes these aggregate production quotas and assessment of annual needs at the same amounts as proposed.
Estimates of Diversion Pursuant to the SUPPORT Act
The SUPPORT Act (21 U.S.C. 826(i)(1)(a)) requires that “in establishing any quota under this section . . ., for [the covered controlled substances], the Attorney General shall estimate the amount of diversion of the [covered controlled substances] that occurs in the United States.” To estimate diversion as is required by the SUPPORT Act, DEA aggregated the active pharmaceutical ingredient (API) of each covered controlled substance by metric weight where the data was available in the aforementioned databases. Based on the individual entries into the aforementioned databases, DEA calculated the estimated amount of diversion by multiplying the strength of the API listed for each finished dosage form by the total amount of units reported to estimate the metric weight in kilograms of the controlled substance being diverted. The estimate of diversion for each of the covered controlled substances is reported below.
Diversion Estimates for 2018 (kg)
In accordance with 21 U.S.C. 826, 21 CFR 1303.11, and 21 CFR 1315.11, the Administrator hereby establishes the 2020 aggregate production quotas for the following schedule I and II controlled substances and the 2020 assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, expressed in grams of anhydrous acid or base, as follows:
|Basic class||Established 2020 quotas (g)|
|2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36)||30|
|2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82)||25|
|2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5)||30|
|Start Printed Page 66019|
|5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog)||40|
|5F-ADB; 5F-MDMB-PINACA (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate)||30|
|5F-AMB (methyl 2-(1-(5-fluoropentyl)-1 H-indazole-3-carboxamido)-3-methylbutanoate)||30|
|5F-APINACA; 5F-AKB48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1 H-indazole-3-carboxamide)||30|
|5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1 H- indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone||25|
|ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1 H-indazole-3-carboxamide)||30|
|ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1 H-indazole-3-carboxamide)||50|
|alpha- Pyrrolidinohexanophenone (α-PHP)||25|
|APINCA, AKB48 (N-(1-adamantyl)-1-pentyl-1 H-indazole-3-carboxamide)||25|
|Start Printed Page 66020|
|Fentanyl related substances||40|
|JWH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole)||35|
|Lysergic acid diethylamide (LSD)||40|
|MAB-CHMINACA; ADB-CHMINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1 H-indazole-3-carboxamide)||30|
|MDMB-CHMICA; MMB-CHMINACA(methyl 2-(1-(cyclohexylmethyl)-1 H-indole-3-carboxamido)-3,3-dimethylbutanoate)||30|
|MDMB-FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1 H-indazole-3-carboxamido)-3,3-dimethylbutanoate)||30|
|NM2201; Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate||25|
|Start Printed Page 66021|
|N- Ethylpentylone, ephylone||30|
|SR-18 and RCS-8 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole)||45|
|SR-19 and RCS-4 (1-Pentyl-3-[(4-methoxy)-benzoyl]indole)||30|
|Amphetamine (for conversion)||14,137,578|
|Amphetamine (for sale)||47,000,000|
|Codeine (for conversion)||3,225,000|
|Codeine (for sale)||30,731,558|
|Diphenoxylate (for conversion)||14,100|
|Diphenoxylate (for sale)||770,800|
|Hydrocodone (for conversion)||1,250|
|Start Printed Page 66022|
|Hydrocodone (for sale)||34,836,854|
|Methadone (for sale)||22,278,000|
|[678,878 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 505,231 grams for methamphetamine mostly for conversion to a schedule III product; and 29,494 grams for methamphetamine (for sale)]|
|Morphine (for conversion)||4,089,000|
|Morphine (for sale)||29,353,655|
|Noroxymorphone (for conversion)||19,169,340|
|Noroxymorphone (for sale)||376,000|
|Oxycodone (for conversion)||914,010|
|Oxycodone (for sale)||67,593,983|
|Oxymorphone (for conversion)||24,525,540|
|Oxymorphone (for sale)||829,051|
|List I Chemicals|
|Ephedrine (for conversion)||25|
|Ephedrine (for sale)||4,136,000|
|Phenylpropanolamine (for conversion)||14,100,000|
|Phenylpropanolamine (for sale)||7,990,000|
|Pseudoephedrine (for conversion)||1,000|
|Pseudoephedrine (for sale)||174,246,000|
The Administrator also establishes aggregate production quotas for all other schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 at zero. In accordance with 21 CFR 1303.13 and 21 CFR 1315.13, upon consideration of the relevant factors, the Administrator may adjust the 2020 aggregate production quotas and assessment of annual needs as needed.
End Supplemental Information
Dated: November 27, 2019.
[FR Doc. 2019-26119 Filed 11-29-19; 8:45 am]
BILLING CODE 4410-09-PStart Printed Page 66023